Rheumatology International

, Volume 38, Issue 12, pp 2217–2224 | Cite as

The role of mirtazapine in patients with fibromyalgia: a systematic review

  • Andreina A. OttmanEmail author
  • Carly B. Warner
  • Jamie N. Brown
Systematic Review


Mirtazapine is commonly used to treat major depressive disorder. Due to its effects on multiple neurotransmitters, it has been investigated for possible benefits in patients with fibromyalgia. The objective of this systematic review is to assess the efficacy and safety of mirtazapine in the treatment of patients with fibromyalgia. Pubmed (1946-May 2018), Embase (1947-May 2018), CENTRAL, and were queried using the search term combination: fibromyalgia, pain, chronic pain, neuralgia, neuropathic pain, chronic widespread pain, or chronic pain syndrome and mirtazapine. Studies appropriate to the objective were evaluated, including three randomized, placebo-controlled trials and one open-label trial, investigating the effect of mirtazapine in patients with fibromyalgia. In patients with fibromyalgia, treatment with mirtazapine resulted in improvements in pain, sleep, and quality of life. Study durations ranged from 6 to 13 weeks and studies used varying dosing strategies for mirtazapine. Minor occurrences of somnolence, weight gain, nasopharyngitis, dry mouth, and increased appetite were reported with mirtazapine use. Based on the reviewed literature, mirtazapine appears to be a promising therapy to improve pain, sleep, and quality of life in patients with fibromyalgia. These benefits were demonstrated in patients that were treatment naïve and those that had failed previous therapies. Additional clinical evidence through larger and longer length trials would be of benefit to further define the role of mirtazapine for patients with fibromyalgia.


Pain Chronic pain Fatigue Sleep Quality of life Depression 


Author contributions

All authors substantially contributed to the concept and design, acquisition of the data, or analysis and interpretation; drafting or revision of the manuscript for important intellectual content; and gave final approval for submission and publication.


No external funding was secured for this review.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to disclose.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Financial disclosure

The authors report no financial relationships relevant to this article to disclose.


  1. 1.
    Mirtazapine tablets [package insert] (2016) Updated 2016. Mylan Pharmaceuticals Inc., MorgantownGoogle Scholar
  2. 2.
    Queiroz LP (2013) Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 17:356CrossRefGoogle Scholar
  3. 3.
    Kia S, Choy E (2017) Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines 5:E20CrossRefGoogle Scholar
  4. 4.
    Clauw DJ (2014) Fibromyalgia: a clinical review. JAMA 311:1547–1555CrossRefGoogle Scholar
  5. 5.
    Phillips K, Clauw DJ (2013) Central pain mechanisms in the rheumatic diseases: future directions. Arthritis Rheum 65:291–302CrossRefGoogle Scholar
  6. 6.
    Kato K, Sullivan PF, Evengård B, Pedersen NL (2009) A population-based twin study of functional somatic syndromes. Psychol Med 39:497–505CrossRefGoogle Scholar
  7. 7.
    Jahan F, Nanji K, Qidwai W, Qasim R (2012) Fibromyalgia syndrome: an overview of pathophysiology, diagnosis and management. Oman Med J 27:192–195CrossRefGoogle Scholar
  8. 8.
    Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172CrossRefGoogle Scholar
  9. 9.
    Wolfe F, Clauw DJ, Fitzcharles MA et al (2011) Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 38:1113–1122CrossRefGoogle Scholar
  10. 10.
    Wolfe F, Clauw DJ, Fitzcharles MA, at al (2016) Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 46:319–329CrossRefGoogle Scholar
  11. 11.
    Macfarlane GJ, Kronisch C, Dean LE et al (2017) EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 76:318–328CrossRefGoogle Scholar
  12. 12.
    Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. (updated March 2011). The Cochrane Collaboration. Accessed 23 May 2018
  13. 13.
    Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269CrossRefGoogle Scholar
  14. 14.
    Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefGoogle Scholar
  15. 15.
    Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712–716CrossRefGoogle Scholar
  16. 16.
    Samborski W, Lezańska-Szpera M, Rybakowski JK (2004) Effects of antidepressant mirtazapine on fibromyalgia symptoms. Rocz Akad Med Bialymst 49:265–269PubMedGoogle Scholar
  17. 17.
    Yeephu S, Suthisisang C, Suttiruksa S, Prateepavanich P, Limampai P, Russell IJ (2013) Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. Ann Pharmacother 47:921–932CrossRefGoogle Scholar
  18. 18.
    Miki K, Murakami M, Oka H, Onozawa K, Yoshida S, Osada K (2016) Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain 157:2089–2096CrossRefGoogle Scholar
  19. 19.
    Suttiruksa S, Yeephu S, Prateepavanich P, Suthisisang C (2016) Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial. Asian Biomed 10:435–445Google Scholar
  20. 20.
    Verbunt JA, Pernot DH, Smeets RJ (2008) Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes 6:8CrossRefGoogle Scholar
  21. 21.
    Theadom A, Cropley M, Humphrey KL (2007) Exploring the role of sleep and coping in quality of life in fibromyalgia. J Psychosom Res 62:145–151CrossRefGoogle Scholar
  22. 22.
    Bigatti SM, Hernandez AM, Cronan TA, Rand KL (2008) Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum 59:961–967CrossRefGoogle Scholar
  23. 23.
    Lexi-Comp Online (2018) Lexi-Comp, Inc., Hudson, Ohio. Available at: Accessed 19 Jan 2018

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2018

Authors and Affiliations

  1. 1.Geriatric Research, Education, and Clinical CenterDurham Veterans Affairs Health Care SystemDurhamUSA
  2. 2.Pharmacy Department (119)Durham VA Medical CenterDurhamUSA

Personalised recommendations